Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,996
  • Shares Outstanding, K 20,821
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,600 K
  • EBIT $ -6 M
  • EBITDA $ -5 M
  • 60-Month Beta 2.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.65
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $-0.07 on 11/14/25
  • Next Earnings Date 04/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5407 +16.48%
on 02/19/26
0.7500 -16.03%
on 02/26/26
-0.0090 (-1.41%)
since 02/04/26
3-Month
0.5407 +16.48%
on 02/19/26
1.0400 -39.44%
on 01/08/26
-0.2795 (-30.74%)
since 12/04/25
52-Week
0.4000 +57.45%
on 06/03/25
2.1100 -70.15%
on 09/08/25
-0.4702 (-42.75%)
since 03/04/25

Most Recent Stories

More News
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity

KAPA : 0.6298 (+0.90%)
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung...

KAPA : 0.6298 (+0.90%)
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

CSO Neil Bhowmick to deliver company presentation and will be available for investor meetings

KAPA : 0.6298 (+0.90%)
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Company recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer

KAPA : 0.6298 (+0.90%)
Kairos Pharma Provides Shareholder Update

Company makes important progress in 2025 and looks ahead into 2026

KAPA : 0.6298 (+0.90%)
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data

KAPA : 0.6298 (+0.90%)
Kairos Pharma Approves RSUs and Cash Bonuses

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kairos Pharma,...

KAPA : 0.6298 (+0.90%)
Kairos Pharma to Present at ESMO Congress 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kairos Pharma,...

KAPA : 0.6298 (+0.90%)
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present...

KAPA : 0.6298 (+0.90%)
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety data Company to host virtual KOL discussion...

KAPA : 0.6298 (+0.90%)

Business Summary

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based...

See More

Key Turning Points

3rd Resistance Point 0.6870
2nd Resistance Point 0.6689
1st Resistance Point 0.6493
Last Price 0.6298
1st Support Level 0.6116
2nd Support Level 0.5935
3rd Support Level 0.5739

See More

52-Week High 2.1100
Fibonacci 61.8% 1.4568
Fibonacci 50% 1.2550
Fibonacci 38.2% 1.0532
Last Price 0.6298
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar